Answers are grounded in this paper and cite their sources.
Somatic hypermutation (SHM) in immunoglobulin genes is required for high affinity antibody-antigen binding. Cultured cell systems, mouse model systems, and human genetic deficiencies have been the key players in identifying likely SHM pathways, whereas "pure" biochemical approaches have been far less prominent, but change appears imminent. Here we comment on how, when, and why biochemistry is likely to emerge from the shadows and into the spotlight to elucidate how the somatic mutation of antibody variable (V) regions is generated.
No takes yet. Share an insight, caveat, or question.
Goodman et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: